365体育官方网址Jim joined NEA in 2001, he is a retired General Partner and a current Strategic Adviser. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Present board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Cerecor Inc., Clovis Oncology, GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Psyadon Pharmaceuticals, Roka Bioscience, Senseonics, Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. Jim formerly served on the boards of CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca), Pharmion (acquired by Celgene), Inhibitex, Inc. (NASDAQ: INHX, acquired by Bristol-Myers Squibb), and Peptimmune, Inc. Prior to NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.